Phase II Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Lacnotuzumab (Primary) ; Spartalizumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Sep 2021 Results of a single-arm phase II study assessing efficacy and safety of PDR001 in the treatment of esophageal squamous cell carcinoma (ESCC) in Korea, presented at the 46th European Society for Medical Oncology Congress.
- 05 May 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2020 Status changed from not yet recruiting to recruiting.